{"id":"008a08cb-929b-5bfe-a27d-a948b3eeca2e","stable_key":"10629adf-a816-5b7b-82db-a76bfbb946f2:bg-immunogenicity-in-genetic-responders","predicate":"increases","statement":"Eligible patients receiving GD2/GD3 vaccine were randomly assigned to group 1 with 54 patients to receive no beta-glucan or group 2 with 53 patients to receive an oral beta-glucan regimen during the first 5 weeks of vaccine priming, and from week 6 onwards all 107 patients received oral beta-glucan during vaccine boost, adding oral beta-glucan during the first 5 weeks of vaccine priming elicited a higher anti-GD2 IgG1 antibody response in group 2 at 1.80 with 90% CI 0.12 to 3.39 and P = .08 against a planned type I error of 0.10, antibody titre correlated significantly with dectin-1 single nucleotide polymorphism, and the genotype frequency, seroconversion rates and vaccine-related toxic effects were similar in the 2 groups.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"97c7dfa0-98ef-58f2-9fa3-d68074c04195","mechanism_event_label":"Starting the glucan earlier raised the antibody the vaccine was meant to raise, at a significance bar the trial had set in advance at one in ten.","subject":{"id":"919e84e7-6b11-59de-a10b-8b844b1e72f3","slug":"yeast-beta-glucan","display_name":"Yeast beta-(1->3)/(1->6)-glucan","entity_type_key":"chemical_species"},"object":{"id":"cc4cfdd4-7fdb-52be-a653-711b1de9738a","slug":"anti-gd2-igg1","display_name":"Anti-GD2 IgG1 antibody titre","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"97c7dfa0-98ef-58f2-9fa3-d68074c04195","stable_key":"10629adf-a816-5b7b-82db-a76bfbb946f2:bg-immunogenicity-in-genetic-responders-event","event_type":"observed_intervention","label":"Starting the glucan earlier raised the antibody the vaccine was meant to raise, at a significance bar the trial had set in advance at one in ten.","description":"Eligible patients receiving GD2/GD3 vaccine were randomly assigned to group 1 with 54 patients to receive no beta-glucan or group 2 with 53 patients to receive an oral beta-glucan regimen during the first 5 weeks of vaccine priming, and from week 6 onwards all 107 patients received oral beta-glucan during vaccine boost, adding oral beta-glucan during the first 5 weeks of vaccine priming elicited a higher anti-GD2 IgG1 antibody response in group 2 at 1.80 with 90% CI 0.12 to 3.39 and P = .08 against a planned type I error of 0.10, antibody titre correlated significantly with dectin-1 single nucleotide polymorphism, and the genotype frequency, seroconversion rates and vaccine-related toxic effects were similar in the 2 groups.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"54eb8c5d-8396-5f38-a348-0f75c85ea496","slug":"gd2-gd3-vaccine","display_name":"A GD2 and GD3 ganglioside conjugate vaccine","entity_type_key":"chemical_species"},"role":"combination_partner","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"98a27026-6642-550a-9523-e5d7de9e3367","slug":"clec7a-rs3901533","display_name":"The dectin-1 rs3901533 single nucleotide polymorphism","entity_type_key":"gene"},"role":"associated_genotype","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"117c178c-d74c-5c56-b2d6-d3956ad70c03","slug":"clec7a","display_name":"Dectin-1 / CLEC7A","entity_type_key":"protein"},"role":"host_receptor","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"919e84e7-6b11-59de-a10b-8b844b1e72f3","slug":"yeast-beta-glucan","display_name":"Yeast beta-(1->3)/(1->6)-glucan","entity_type_key":"chemical_species"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""},{"entity":{"id":"cc4cfdd4-7fdb-52be-a653-711b1de9738a","slug":"anti-gd2-igg1","display_name":"Anti-GD2 IgG1 antibody titre","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":4,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/glucan-research/36547975.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"156766d12dba66e36fba78a5ca31f9c41f50f88f74817ba4d545a7a3ed5e23f2\", \"start_char\": 0, \"end_char\": 2766, \"text_sha256\": \"156766d12dba66e36fba78a5ca31f9c41f50f88f74817ba4d545a7a3ed5e23f2\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Phase 2 randomised clinical trial isolating the adjuvant effect during the vaccine priming phase","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Oral beta-glucan during the first 5 weeks of GD2/GD3 vaccine priming against none, with all patients receiving glucan from week 6 onward","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"A randomised design that isolates one adjuvant window, with a prespecified type I error of 0.10 rather than the conventional 0.05. The endpoint is an antibody titre, not survival.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Beta-glucan research collection; topical membership is not evidence of a direct clinical effect, and each preparation is recorded as its own entity with no family link joining any pair.","comparator":null,"unit":null,"notes":"","entity":{"slug":"beta-glucan","display_name":"Beta-glucan","entity_type_key":"chemical_species"}},{"dimension":"organism","value_text":"Human","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Starting the glucan earlier raised the antibody the vaccine was meant to raise, at a significance bar the trial had set in advance at one in ten.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[bg-p36547975] Effect of Oral β-Glucan on Antibody Response to Ganglioside Vaccine in Patients With High-Risk Neuroblastoma: A Phase 2 Randomized Clinical Trial. (2023). https://pubmed.ncbi.nlm.nih.gov/36547975/ DOI: 10.1001/jamaoncol.2022.5999","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"High-risk neuroblastoma","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"f2dacefd-bfb7-5eef-918a-9e8946c35e10","evidence_kind":"source_excerpt","locator":"Lines 359-370","start_line":359,"end_line":370,"excerpt":"### bg-immunogenicity-in-genetic-responders\nEligible patients receiving GD2/GD3 vaccine were randomly assigned to group 1 with 54 patients to receive no beta-glucan or group 2 with 53 patients to receive an oral beta-glucan regimen during the first 5 weeks of vaccine priming, and from week 6 onwards all 107 patients received oral beta-glucan during vaccine boost, adding oral beta-glucan during the first 5 weeks of vaccine priming elicited a higher anti-GD2 IgG1 antibody response in group 2 at 1.80 with 90% CI 0.12 to 3.39 and P = .08 against a planned type I error of 0.10, antibody titre correlated significantly with dectin-1 single nucleotide polymorphism, and the genotype frequency, seroconversion rates and vaccine-related toxic effects were similar in the 2 groups.\nCondition category: normal\nnutrient_topic: Beta-glucan research collection; topical membership is not evidence of a direct clinical effect, and each preparation is recorded as its own entity with no family link joining any pair.\nplain_language: Starting the glucan earlier raised the antibody the vaccine was meant to raise, at a significance bar the trial had set in advance at one in ten.\norganism: Human\ntissue_or_cell_type: High-risk neuroblastoma\nexperimental_model: Phase 2 randomised clinical trial isolating the adjuvant effect during the vaccine priming phase\nlimitations: A randomised design that isolates one adjuvant window, with a prespecified type I error of 0.10 rather than the conventional 0.05. The endpoint is an antibody titre, not survival.\nexposure: Oral beta-glucan during the first 5 weeks of GD2/GD3 vaccine priming against none, with all patients receiving glucan from week 6 onward\nevidence_span: {\"source_cache\": \"artifacts/glucan-research/36547975.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"156766d12dba66e36fba78a5ca31f9c41f50f88f74817ba4d545a7a3ed5e23f2\", \"start_char\": 0, \"end_char\": 2766, \"text_sha256\": \"156766d12dba66e36fba78a5ca31f9c41f50f88f74817ba4d545a7a3ed5e23f2\"}\n[bg-p36547975] Effect of Oral β-Glucan on Antibody Response to Ganglioside Vaccine in Patients With High-Risk Neuroblastoma: A Phase 2 Randomized Clinical Trial. (2023). https://pubmed.ncbi.nlm.nih.gov/36547975/ DOI: 10.1001/jamaoncol.2022.5999","model_system":"Phase 2 randomised clinical trial isolating the adjuvant effect during the vaccine priming phase","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [bg-p36547975] Effect of Oral β-Glucan on Antibody Response to Ganglioside Vaccine in Patients With High-Risk Neuroblastoma: A Phase 2 Randomized Clinical Trial. (2023). https://pubmed.ncbi.nlm.nih.gov/36547975/ DOI: 10.1001/jamaoncol.2022.5999","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"74dc223d-8289-57bf-a731-d220fa017c1e","stable_key":"import-10629adf-a816-5b7b-82db-a76bfbb946f2","title":"Beta-glucan: a structural family rather than an agent, what decides whether a bound glucan actually signals, the complement route that a cereal and a yeast preparation share, and the unequal human evidence behind each (2026-09-22)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"7c62f2d2f8d99b650e6dc26a505b0f053ae1c8bdb38099d4dfc0771f65287461","revision_id":"a53bb794-0a4b-525d-9cf7-22b46a5403b0","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}